NKTR-181 structure
|
Common Name | NKTR-181 | ||
|---|---|---|---|---|
| CAS Number | 1211231-76-3 | Molecular Weight | 595.721 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 679.2±55.0 °C at 760 mmHg | |
| Molecular Formula | C31H49NO10 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 364.6±31.5 °C | |
Use of NKTR-181A novel, long-acting and orally active, selective mu-opioid agonist that displays higher binding affinity (Ki=237 nM) at the MOR than kappa and delta opioid receptors (>100-fold); demonstrates maximum analgesic activity comparable to that of oxycodone in hot-plate latency and acetic-acid writhing models, reduces its rate of entry across the blood-brain barrier compared with traditional mu-opioid agonists. Pain Phase 3 Clinical |
| Name | oxycodegol |
|---|---|
| Synonym | More Synonyms |
| Description | A novel, long-acting and orally active, selective mu-opioid agonist that displays higher binding affinity (Ki=237 nM) at the MOR than kappa and delta opioid receptors (>100-fold); demonstrates maximum analgesic activity comparable to that of oxycodone in hot-plate latency and acetic-acid writhing models, reduces its rate of entry across the blood-brain barrier compared with traditional mu-opioid agonists. Pain Phase 3 Clinical |
|---|---|
| References | References 1. Miyazaki T, et al. J Pharmacol Exp Ther. 2017 Oct;363(1):104-113. 2. Webster L, et al. Pain Med. 2017 Mar 10. doi: 10.1093/pm/pnw344. View Related Products by Target Opioid Receptor Pain |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 679.2±55.0 °C at 760 mmHg |
| Molecular Formula | C31H49NO10 |
| Molecular Weight | 595.721 |
| Flash Point | 364.6±31.5 °C |
| Exact Mass | 595.335632 |
| LogP | -0.49 |
| Vapour Pressure | 0.0±2.2 mmHg at 25°C |
| Index of Refraction | 1.560 |
| (5α,6α)-6-(2,5,8,11,14,17-Hexaoxanonadecan-19-yloxy)-3-methoxy-17-methyl-4,5-epoxymorphinan-14-ol |
| Morphinan-14-ol, 4,5-epoxy-6-(3,6,9,12,15,18-hexaoxanonadec-1-yloxy)-3-methoxy-17-methyl-, (5α,6α)- |
| oxycodegol |